WASHINGTON — In this video, Manos Perros, PhD, president and CEO of Entasis Therapeutics, summarizes a panel discussion about how prescribing habits for new antibiotics impact the antimicrobial market.
“We need to continue innovating and bringing new drugs to the market that can treat drug-resistant infections,” Perros said.
Over the last decade, about 10 new antibiotics have been approved and commercialized as a response to the growing threat of antimicrobial resistance. However, while “trying to commercialize these new projects,” companies and stakeholders are “running out of money and, for a number of them, going bankrupt,” according to Perros.
Prescribing practices are shifting from broad-spectrum antibiotics to targeted therapies, but in practice, the uptake is slow.
“We discussed what makes that change more challenging,” Perros said. “One of the main issues is the pricing and reimbursement environment.”
Disclosures: Perros is the CEO and president of Entasis Therapeutics.